Asia Deal Watch: Takeda On A Deal Spree
Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.
You may also be interested in...
European Clinical-Stage Cancer Vaccine Gains South Korean Support
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.
Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
Takeda To Press On With Core R&D Strategy Post-Shire
Takeda continues to pursue the transformation of its R&D activities, which has already led to expansion of the pipeline, but will continue with core strategies including partnering even after the huge Shire acquisition.